Rapport Therapeutics, Inc./$RAPP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Ticker
$RAPP
Sector
Health
Primary listing
Employees
69
Headquarters
Website
RAPP Metrics
BasicAdvanced
$562M
-
-$2.51
-
-
Price and volume
Market cap
$562M
52-week high
$17.45
52-week low
$6.43
Average daily volume
175K
Financial strength
Current ratio
22.75
Quick ratio
21.925
Long term debt to equity
3.834
Total debt to equity
4.502
Profitability
EBITDA (TTM)
-100.79
Management effectiveness
Return on assets (TTM)
-20.14%
Return on equity (TTM)
-29.42%
Valuation
Price to book
2.13
Price to tangible book (TTM)
2.13
Price to free cash flow (TTM)
-7.066
Free cash flow yield (TTM)
-14.15%
Free cash flow per share (TTM)
-2.181
Growth
Earnings per share change (TTM)
-84.15%
Bulls say / Bears say
Rapport Therapeutics' lead candidate, RAP-219, is progressing through a Phase 2a trial for refractory focal epilepsy, with topline results expected in September 2025, indicating potential for significant clinical advancements. (investors.rapportrx.com)
Analysts have set an average one-year price target of $35 for RAPP, suggesting a potential upside of approximately 183.17% from its current price, reflecting strong confidence in the company's growth prospects. (stockanalysis.com)
FMR LLC acquired 5,486,468 shares of Rapport Therapeutics at $20.48 per share, representing a 15% stake, indicating substantial institutional confidence in the company's future. (gurufocus.com)
Rapport Therapeutics reported a net loss of $19.98 million in Q4 2024, highlighting ongoing financial challenges typical of clinical-stage biotech companies. (investors.rapportrx.com)
The company's stock price has experienced significant volatility, with a 52-week range between $6.43 and $29.74, which may concern risk-averse investors. (google.com)
As a clinical-stage biotech firm, Rapport Therapeutics faces inherent risks associated with drug development, including potential delays or failures in clinical trials, which could adversely affect its stock performance. (investors.rapportrx.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RAPP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rapport Therapeutics, Inc. stock?
Rapport Therapeutics, Inc. (RAPP) has a market cap of $562M as of August 08, 2025.
What is the P/E ratio for Rapport Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Rapport Therapeutics, Inc. (RAPP) stock is 0 as of August 08, 2025.
Does Rapport Therapeutics, Inc. stock pay dividends?
No, Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next Rapport Therapeutics, Inc. dividend payment date?
Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders.
What is the beta indicator for Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc. (RAPP) does not currently have a Beta indicator.